Benitec Biopharma Inc.

Benitec Biopharma Inc.

NNASDAQ:BNTC
8.54
USD
-0.50
(-5.53%)
-1.10EPS
348.89MMarket Cap
Feb 15Next Earn

Total Valuation

USD

As of September 30, 2026, Benitec Biopharma Inc. carries a market capitalization of 348.89M, placing it among publicly traded companies globally. Its enterprise value stands at 173.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap348.89M
Enterprise Value173.17M

Important Dates

Benitec Biopharma Inc.'s next confirmed earnings release is scheduled for February 15, 2027.

Earnings Date2/15/2027

Share Statistics

As of September 30, 2026, Benitec Biopharma Inc. has 34.89M shares outstanding.

Shares Outstanding34.89M

Valuation Ratios

These figures are as of September 30, 2026.

PB Ratio2.06
P/TBV Ratio2.06
P/FCF Ratio-26.54
P/OCF Ratio-26.69

Financial Position

As of September 30, 2026, Benitec Biopharma Inc. maintains a current ratio of 19.62, meaning it holds 19.6x the short-term assets needed to cover near-term liabilities.

Current Ratio19.62
Quick Ratio19.43
Debt / Equity0.38
Debt / EBITDA-0.01

Financial Efficiency

Over the twelve months ended September 30, 2026, Benitec Biopharma Inc. posted a negative return on equity (ROE) of -37.61, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -35.99, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 21.50, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-37.61
Return on Assets (ROA)-35.99
Employee Count21.50

Stock Price Statistics

USD

As of the close on November 16, 2026, Benitec Biopharma Inc.'s stock has declined approximately 35.11% over the past 52 weeks. The 50-day moving average sits at 9.59, while the 200-day moving average is 11.37.

52-Week Price Change-35.11%
50-Day Moving Average9.59
200-Day Moving Average11.37

Income Statement

USD

Over the twelve months ended September 30, 2026, Benitec Biopharma Inc. generated - - in revenue and converted that into -49.51M in net income, yielding earnings per share of -1.10. EBITDA reached -55.38M, while operating income came in at -55.87M.

Operating Income-55.87M
Pretax Income-49.51M
Net Income-49.51M
EBITDA-55.38M
EBIT-55.87M
Earnings Per Share (EPS)-1.10

Balance Sheet

USD

As of September 30, 2026, Benitec Biopharma Inc. holds 176.37M in cash and equivalents against 642,000.00 in total debt, resulting in a net debt position of -176.37M. Total book value stands at 169.65M, with working capital of 169.03M providing operational flexibility.

Cash & Cash Equivalents176.37M
Total Debt642,000.00
Net Debt-176.37M
Equity (Book Value)169.65M
Book Value Per Share4.86
Working Capital169.03M

Cash Flow

USD

Benitec Biopharma Inc. produced -16.79M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -94,000.00 in capital expenditures, free cash flow totaled -16.88M - equivalent to -0.38 per share.

Operating Cash Flow-16.79M
Capital Expenditures-94,000.00
Free Cash Flow-16.88M
FCF Per Share-0.38

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -3.77: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -28.37, meaning Benitec Biopharma Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-28.37
FCF Yield-3.77

Stock Splits

Benitec Biopharma Inc.'s most recent stock split took place on July 26, 2023 with a 17:1 split ratio.

Last Split Date7/26/2023
Split Ratio17:1

Scores

As of September 30, 2026, Benitec Biopharma Inc. has an Altman Z-Score of 20.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score20.01